Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 531633 | NSE Symbol : LINCOLN | ISIN : INE405C01035 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
15-May-2025	22-May-2025	Accounts	Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2025 inter alia to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31 2025. Recommended a Final Dividend of Rs. 1.80/- (i.e 18%) per equity shares of face value 10/- each for the Financial year Ended 31st March, 2025 subject to approval of the members at the ensuing A.G.M of the Company. (As Per BSE Announcement dated on 22.05.2025)
05-Feb-2025	13-Feb-2025	Quarterly Results	LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Quarter And Nine Months Ended 31st December 2024 And Other Business if any. UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2024 (As Per BSE Announcement Dated on: 13/02/2025)
05-Nov-2024	14-Nov-2024	Quarterly Results	LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended on September 30 2024. UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2024 (As Per BSE Announcement Dated on 14.11.2024)
30-Jul-2024	08-Aug-2024	Quarterly Results	LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30 2024 along with any other business if any. Out come of Un-Audited Financial Results for the Quarter Ended 30-June-2024 (As Per BSE Announcement Dated on 08.08.2024)
08-May-2024	16-May-2024	Accounts	LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 inter alia to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31 2024. Outcome of Audited Financial Results for Quarter and year Ended on 31st March, 2024 (As Per BSE Announcement dated on 16.05.2024)
01-Apr-2024	01-Apr-2024	Change in Directors	Board Meeting Outcome for Appointment of Non-Executive Independent Directors and Approval of Postal Ballot.
25-Jan-2024	08-Feb-2024	Quarterly Results	LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve the Un-Audited Financial Results for the Quarter And Nine-Months Ended On December 31 2023 along with any other business if any. OUTCOME OF THE BOARD MEETING (As per BSE Announcement Dated on 08/02/2024)
23-Oct-2023	02-Nov-2023	Quarterly Results	LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2023 ,inter alia, to consider and approve un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended on September 30, 2023. LINCOLN PHARMACEUTICALS LIMITED has informed BSE about Board Meeting to be held on 02 Nov 2023 to consider financial statements for the period ended September 2023. Financial results. Un-Audited Financial Results for the Quarter and half year ended 30.09.2023 Un-Audited Financial Results for Quarter and Half year ended on 30.09.2023 (As Per BSE Announcement Dated on 02.11.2023) Intimation of Placing of the matter before the board of Directors w.r.t Identification of Non-Compliance of Regulation 17(1) of SEBI (Listing Obligations & Disclosure Requirement) Regulation, 2015 (''Listing Regulations'') And subsequent action taken by the exchange in this matter. (As Per BSE Announcement Dated on 03.11.2023)
28-Jul-2023	10-Aug-2023	Quarterly Results	LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30 2023 along with any other business if any. Unaudited Standalone & Consolidated Financial Results of the Company for the Quarter ended 30.06.2023. (As Per BSE Announcement dated on 10.08.2023)
15-May-2023	25-May-2023	Dividend	LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 inter alia to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31 2023. Financial Results (standalone and consolidated) for the Quarter and Year Ended March 31, 2023 FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND YEAR ENDED 31.03.2023 The Board of Directors at their meeting held on today i.e. 25th May, 2023 has recommended dividend of Rs. 1.50/- (i.e 15% per share) per equity share of face value of Rs. 10/- for the year ended 31.03.2023 subject to approval of Members at the ensuing Annual General Meeting of the Company. (As per BSE Announcement Dated on 25/05/2023) We enclosed herewith the copies of published newspaper advertisement with respect to the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2023. (As Per BSE Announcement Dated on 26/05/2023)
31-Jan-2023	09-Feb-2023	Quarterly Results	LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 inter alia to consider and approve the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine-months ended on December 31 2022 along with any other business if any. Outcome of the Board Meeting held today (As Per BSE Announcement Dated on 09/02/2023)
31-Jan-2023	31-Jan-2023	Others	Consequent upon cessation of Mr. Ishwarlal Ambalal Patel, Independent Director of the Company due to his untimely demise, the Board of Directors has reconstituted the committees effective from conclusion of the meeting of Board of Directors held today i.e. on January 31, 2023.
31-Oct-2022	10-Nov-2022	Quarterly Results	LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 inter alia to consider and approve Board meeting to consider and approve Un-audited financial Results (standalone and Consolidated) for the quarter and half year ended September 30 2022. other business if any. Outcome of the Board Meeting to approve Unaudited Standalone & Consolidated Financial Results for the Quarter and half year ended on 30.09.2022 Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended on 30.09.2022 Appointment of Ms. Trusha Shah (Membership No:A59416) as the Company Secretary & Compliance Officer at the Board Meeting held on 10.11.2022. (As per BSE Announcement Dated on 10/11/2022)
28-Jul-2022	09-Aug-2022	Quarterly Results	LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2022 inter alia to consider and approve board meeting on 9th August for folloWing agenda 1) To consider and approve un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30 2022; 2) To consider appointment of Mr. Anand A. Patel as an additional and Whole Time Director in the category of executive director (Promoter & Promoter Group) of the Company; 3) To consider appointment of M/s. Samir M. Shah & Associates Chartered Accountants (Firm Reg. No. 122377W) Ahmedabad as the statutory auditors of the Company for a period of five years from the conclusion of 28th Annual General Meeting (AGM) till the conclusion of the 33th AGM in place of retiring auditors and recommended for final approval of the members at the ensuing AGM; 4) Any other business with the permission of the Chairman if any. OUTCOME OF BOARD MEETING -RESULTS Details of appointment of Additional Director (Category: Whole Time Director) and resignation by Director is attached herewith Appointment of New Statutory Auditor subject to approval of members at Ensuing AGM as per the letter attached (As Per BSE Announcement Dated on 09.08.2022)
11-May-2022	19-May-2022	Accounts	Audited Results LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2022 ,inter alia, to consider and approve audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31, 2022 Lincoln Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 19, 2022, inter alia, has recommended a dividend of Rs. 1.50/- (i.e. 15% per share} per equity share of face value of Rs. 10/- for the year ended March 31, 2022, for approval of the members at the ensuring annual general meeting (AGM) of the Company. Outcome of the Board Meeting board consider audited financial result (standalone & consolidated) for the quarter and year ended March 31, 2022. (As Per BSE Announcement Dated on 19.05.2022)

1 2

LOGIN HERE

Lincoln Pharmaceuticals Ltd

Board Meeting